Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
16.81
+0.44 (2.69%)
May 27, 2026, 1:06 PM EDT - Market open
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $392.25 million as of May 27, 2026. Its market cap has increased by 232.03% in one year.
Market Cap
392.25M
Enterprise Value
169.85M
1-Year Change
232.03%
Ranking
Category
Stock Price
$16.81
Market Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $392.25M, a decrease of -90.50%. That is a compound annual growth rate of -37.89%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 26, 2026 | 381.98M | -41.58% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
| Jun 17, 2021 | 4.13B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Prelude Therapeutics | 429.47M |
| Ovid Therapeutics | 427.40M |
| vTv Therapeutics | 426.95M |
| Sutro Biopharma | 423.64M |
| Monopar Therapeutics | 422.83M |
| Zura Bio | 413.68M |
| Century Therapeutics | 407.60M |
| Enanta Pharmaceuticals | 405.64M |